ERBB2 and breast cancer: Trastuzumab (Herceptin) is a humanized monoclonal antibody which binds to the ectodomain of HER2 [4] and was the first HER2-targeted agent approved by the US Food and Drug Administration (in 1998) for clinical use in the breast cancer patients.